ArticleJournal of global health2026
Impact and cost-effectiveness of two interventions to prevent paediatric respiratory syncytial virus disease in Cameroon: a modelling approach.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preventive interventions for respiratory syncytial virus (RSV) disease are emerging and have been approved for support by Gavi, the Vaccine Alliance. However, their cost-effectiveness is under-researched in low- and middle-income countries, where RSV burden remains the highest. We modelled the potential impact and cost-effectiveness of two interventions for the prevention of RSV in young children in Cameroon, a Gavi-eligible country with a gross domestic product (GDP) per capita of USD 1563 in 2022. Methods: We used a static proportionate outcomes model to estimate the health and economic burden of RSV with and without a single dose of long-acting infant monoclonal antibody (mAb, nirsevimab) or maternal vaccine (bivalent RSVpreF) administered year-round over the period 2025-2034. We gathered data from the scientific literature, Demographic and Health Surveys, World Health Organization/UNICEF country profiles, clinical trials, and local experts. We calculated RSV cases, clinic visits, hospital admissions, and deaths for each week of age from birth to five years. The primary outcome measure was the incremental cost per disability-adjusted life year (DALY) averted from a government perspective, compared to no intervention. We explored cost-effectiveness over a range of cost-effectiveness thresholds expressed as proportions of the country's GDP per capita. Due to uncertainty in price per dose and limited country-specific RSV burden data, we ran several deterministic scenarios and performed probabilistic sensitivity analyses. Results: Between 2025 and 2034, we estimated that at USD 5 per dose, the infant mAb (69% coverage, 77% efficacy, 5 months protection) and maternal vaccine (65% coverage, 69% efficacy, 6 months protection) have a notable impact, averting 2267 (27.3%) and 2226 (26.9%) RSV-related deaths among children under five years old, respectively. In this scenario, the incremental cost was similar for both interventions (USD 500 per DALY averted) when compared separately to no intervention, with >90% probability of being cost-effective at a 0.5 GDP per capita (USD 782) threshold. To be cost-effective in Cameroon, at a 0.1 GDP per capita threshold, both interventions must be priced below USD 2.50. Conclusions: Both the infant mAb and maternal vaccine have the potential to be impactful and cost-effective in Cameroon and could be affordable if priced appropriately, with support from Gavi.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.